Showing results (131-140 of 211) with videos related to

Sort By:
Pageof 22
American Journal of Hematology|July 22, 2014
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net studyIda Martinelli, Valerio De Stefano, Alessandra Carobbio, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Acta Oncologica (Stockholm, Sweden)|September 9, 2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational studyFabio Stagno, Massimo Breccia, Mario Annunziata, et al.
American Journal of Hematology|January 24, 2018
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cellsMaria Antonietta Avanzini, Vittorio Abbonante, Paolo Catarsi, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Frontiers in Oncology|June 14, 2021
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian SubstudyLidia Borghi, Gianantonio Rosti, Alessandro Maggi, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2016
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysisMassimo Breccia, Guendalina Graffigna, Sara Galimberti, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
Pageof 22